While I agree with alls disappointment, hopefully this means good news for Remplir. Remember, @bedger, prior to the BH announcement, there were hints between the lines in retrospect. Let's hope this is a large not-so-subtle sign of something bigger in the works.
I can only assume his experience isn't cheap, and if Ravi can pull something off with Remplir and the FDA in a timely manner, it'll be worth every penny...
I'll naively choose to see this as a good sign... I'm still holding anyway.
ill also write, and let's see if we can at least get some information from the stone that is OCC.
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani, page-25
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |